23 results
Thumbnail

- D1.536 - Immunological basis of coexisting slowly progressive insulin-dependent diabetes mellitus (SPIDDM) and Vogt–Koyanagi–Harada disease (VKH)

Thumbnail

- D1.537 - Immunopharmacogenomics as a Systems Medicine Framework for Precision Therapy in Allergic and Immune Mediated Diseases

Thumbnail

- D1.538 - First Report of the SERPING1 c.52-1G>A Variant in a Chinese HAE Pedigree: Severe Abdominal Phenotype Correlated with Attack-Phase Imaging

Thumbnail

- D1.540 - Automated generation of real-world clinical databases in Allergy: a data-driven research framework

Thumbnail

- D1.541 - Addressing Allergy undergraduate education: Strategic Reforms for Specialist-Led Allergy teaching in Medical Curricula. A EAACI Tailored Education Committee Task Force

Thumbnail

D1.539 - Efficacy and safety of sotatercept in pulmonary arterial hypertension: a systematic review and meta‐analysis of randomized controlled trials

Thumbnail

D3.440 - Long-Term Efficacy and Safety of Donidalorsen for Hereditary Angioedema Among Patients in Europe: A Regional Analysis of the OASISplus Study

Thumbnail

D3.441 - Switching to Donidalorsen for Hereditary Angioedema: 1-Year Results From the Phase 3 OASISplus Study

Thumbnail

D3.444 - Efficacy and Safety of Donidalorsen for Patients With Hereditary Angioedema in Europe Who Switched From Prior Long-Term Prophylaxis: Results From the OASISplus Study

Thumbnail

D3.445 - Validation of a Novel Serum-Based Indirect Basophil Activation Test (iBAT) to Evaluate Efficacy of a Pivotal Phase III PQ Grass Immunotherapy Trial

Thumbnail

D3.437 - Impact of benralizumab on fatigue and health-related quality of life in patients with hypereosinophilic syndrome: findings from the NATRON phase 3 trial

Thumbnail

D3.438 - Clinical outcomes with navenibart according to baseline attack rate, body mass index, and age: results of the ALPHA-STAR trial

Thumbnail

D3.439 - Donidalorsen For The Treatment Of Hereditary Angioedema: 1-Year Results From The OASISplus Open-Label Extension Cohort

Thumbnail

D3.442 - Patient-Reported Outcomes With Long-Term Donidalorsen Treatment Among Patients In Europe With Hereditary Angioedema: 1-Year Interim Results From The OASISplus Open-Label Extension Cohort

Thumbnail

D3.443 - Patient-Reported Outcomes With Long-Term Donidalorsen Treatment Among Patients In Europe With Hereditary Angioedema: 1-Year Interim Results From The OASISplus Switch Cohort

Thumbnail

D3.446 - PROTECT Phase I/IIa Clinical Trial Demonstrated Strong Correlation Between Humoral Immune Response and Dose of VLP Peanut in Healthy Participants

Thumbnail

D3.447 - Pre-clinical Toxicology and Immunogenicity Evidence as a Precursor of the Successful Phase I/IIA Study with VLP Peanut

Thumbnail

D3.448 - Use of Sebetralstat as Short-term Prophylaxis for Patients with Hereditary Angioedema: Results from the KONFIDENT-S Study

Thumbnail

- D3.540 - Sources of IL-13 in Acute Versus Chronic Models of Eosinophilic Esophagitis

Thumbnail

- D3.538 - Aeroallergen sensitisation as a risk factor for paediatric eosinophilic esophagitis